All In Biotech

Drug Trial Radar · NCT07078955

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

A Phase 2, Multicenter, Randomized, Open-Labeled, Artificial Tear-Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Dec 2025

Primary completion

Nov 2026

Study completion Mar 2027

Sponsor

Lead sponsor
BRIM Biotechnology Inc.Industry
Sponsor type
Industry
First posted
Jul 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)

Conditions

  • Dry Eye Disease (DED)
  • Keratoconjunctivitis Sicca

Interventions

  • BRM421 Ophthalmic Solution, 0.03%Drug

    A topical drop of 0.03% BRM421 ophthalmic solution.

  • Artificial TearDrug

    A topical drop of Artificial Tear.

  • BRM421 Ophthalmic Solution, 0.06%Drug

    A topical drop of 0.06% BRM421 ophthalmic solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in total corneal fluorescein staining (tCFS) scoreTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Taipei Municipal TuCheng Hospital

    New Taipei City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.